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Background: Component resolution recently identified distinct
sensitization profiles in honey bee venom (HBV) allergy, some of
which were dominated by specific IgE to Api m 3 and/or Api m
10, which have been reported to be underrepresented in
therapeutic HBV preparations.
Objective: We performed a retrospective analysis of
component-resolved sensitization profiles in HBV-allergic
patients and association with treatment outcome.
Methods: HBV-allergic patients who had undergone controlled
honey bee sting challenge after at least 6 months of HBV
immunotherapy (n 5 115) were included and classified as
responder (n 5 79) or treatment failure (n 5 36) on the basis of
absence or presence of systemic allergic reactions upon sting
challenge. IgE reactivity to a panel of HBV allergens was
analyzed in sera obtained before immunotherapy and before
sting challenge.
Results: No differences were observed between responders and
nonresponders regarding levels of IgE sensitization to Api m 1,
Api m 2, Api m 3, and Api m 5. In contrast, Api m 10 specific
IgE was moderately but significantly increased in
nonresponders. Predominant Api m 10 sensitization (>50% of
specific IgE to HBV) was the best discriminator (specificity,
95%; sensitivity, 25%) with an odds ratio of 8.444 (2.127-33.53;
P 5 .0013) for treatment failure. Some but not all therapeutic
HBV preparations displayed a lack of Api m 10, whereas Api m
1 and Api m 3 immunoreactivity was comparable to that of
crude HBV. In line with this, significant Api m 10 sIgG4
induction was observed only in those patients who were treated
with HBV in which Api m 10 was detectable.
Conclusions: Component-resolved sensitization profiles in HBV
allergy suggest predominant IgE sensitization to Api m 10 as a
risk factor for treatment failure in HBV immunotherapy. (J
Allergy Clin Immunol 2016;138:1663-71.)
Key words: Apis mellifera, Hymenoptera venom allergy, HBV al-
lergy, recombinant allergen, allergen-specific immunotherapy, treat-
ment failure
Systemic allergic reaction to Hymenoptera stings affects 0.3%
to 3.5% of the adult population.1,2 Venom immunotherapy (VIT)
protects allergic patients from systemic reactions to subsequent
stings.2,3 The effectiveness of VIT depends on a number of vari-
ables such as treatment duration, venom dose during maintenance
therapy, and type of venom (honey bee [HB] vs vespid) used for
immunotherapy.4-6 Treatment failure is more frequent in HB VIT
than in vespid VIT, ranging from 11% to 23% as compared with
0% to 9%.4-7 A recent retrospective study on the outcome of more
than 1600 sting challenges calculated an odds ratio (OR) of more
than 5 for treatment failure in honey bee venom (HBV) allergy as
compared with VIT in vespid venom allergy.6 This increased risk
of treatment failure in HBV allergy has been suggested to be
associated with differences in venom composition, venom dose
during natural exposure conditions, and differences in sensitiza-
tion profiles.4,7,8
Advances in proteomics and molecular biology have allowed a
detailed characterization of the protein composition of HBV. The
best-characterized HBV allergens are phospholipase A2
(Api m 1), hyaluronidase (Api m 2), and the basic peptide
melittin (Api m 4).9,10 Additional HBV allergens of lower abun-
dance have been cloned and characterized such as acid phospha-
tase (Api m 3),11 dipeptidylpeptidase IV (Api m 5),12 icarapin
(Api m 10),13,14 and others as recently reviewed.15 Analysis of
different venom preparations have shown that Api m 3 and Api
m 10, while present in the crude HBV, are absent or underrepre-
sented in preparations used for HBV immunotherapy.13 These
findings were supported by subsequent observations that in pa-
tients with dominant sensitization to Api m 10, IgE reactivity to
HBV could be inhibited by crude HBV preparations but not by
therapeutic HBV preparations.8 In addition, HBV-allergic pa-
tients who had undergone VIT displayed a strong induction of
sIgG4 to Api m 1, Api m 2, and Api m 4, whereas no or little in-
duction of sIgG4 to Api m 3 and Api m 10 could be detected.
8 On
the basis of these 3 lines of evidence, we hypothesized that the
absence or underrepresentation of Api m 3 and Api m 10 in ther-
apeutic HBV preparations may have an impact on the treatment
outcome of VIT and that distinct sensitization profiles, for
example, with predominant IgE reactivity to Api m 3 and/or
Api m 10, may represent a potential risk factor for treatment fail-
ure of VIT in HBV allergy. To address this issue, we here retro-
spectively analyzed the molecular sensitization profiles in HBV-
allergic patients who had undergone controlled HB sting chal-
lenge after at least 6 months of HBV.
METHODS
Patients
Sera from HBV-allergic patients who had undergone controlled HB sting
challenge after at least 6months ofHBVimmunotherapy at amaintenance dose
of 100mg BVwere included in the study (n5 115) and classified as responder,
Abbreviations used
AUC: Area under the ROC curve
HBV: Honey bee venom
HB: Honey bee
LOD: Limit of detection
NLR: Negative likelihood ratio
OR: Odds ratio
PLR: Positive likelihood ratio
ROC: Receiver operating characteristic
sIgE: Specific IgE
VIT: Venom immunotherapy
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that is, protected (n5 79), or treatment failure, that is, not protected (n5 36), on
the basis of the absence or presence of systemic allergic reactions upon sting
challenge. The study was performed retrospectively using banked sera from
patients initiated on HB VIT during August 1993 and November 2013 in 6
different clinical allergy centers that routinely perform sting challenge testing,
and was approved by respective local ethic committees. Diagnosis of HBV
allergy was based on a combination of patient’s history of a systemic sting
reaction, a positive skin test result, and positive specific IgE (sIgE) to HBV
(>_0.35 kUA/L; ImmunoCAP i1), as recently described.
8 All centers were asked
to include patients at a 2:1 ratio of responders versus nonresponders for which
they could provide serum samples obtained before initiation of VITand during
VIT before sting challenge. For each patient, the following data were obtained
from the records: history and grade of anaphylactic HB sting reaction (accord-
ing to Ring & Messmer),16 skin test results, serology and tryptase levels at the
time of initial diagnosis, date and treatment protocol of VIT, concomitant yel-
low jacket VIT, type, maintenance dose, and duration of HB VIT before sting
challenge, systemic reactions during HB VIT, symptoms of systemic allergic
reactions, and antihypertensive medication during sting challenge.
Statistical analysis
Statistical analysis was performed using the nonparametric Mann-Whitney
U test for unpaired data and theWilcoxon signed-rank test for paired data. ORs
were calculated from contingency tables using the Fisher exact test on Graph
Pad Prism 6 software. P values of less than .05 were regarded as significant.
Calculation of diagnostic accuracy measures was performed using SPSS
(IBMSPSS Statistics, Version 22.0.0.0, Ehningen,Germany) and the open sta-
tistical software environment R.17 These were sensitivity, specificity, positive
likelihood ratio (PLR)5 sensitivity/(12 specificity), negative likelihood ratio
(NLR)5 (12 sensitivity)/specificity, receiver operating characteristic (ROC)
curve, and area under the ROC curve (AUC).
For additional information on allergens, sIgE and sIgG4 measurements,
antisera, and immunoblot analysis, please see the Methods section in the
Online Repository at www.jacionline.org.
RESULTS
IgE reactivity to HBV allergens in HBV-allergic
patients before the start of VIT
The frequency of IgE sensitization (>_0.35 kUA/L) to Api m 1,
Api m 2, Api m 3, Api m 5, and Api m 10 of the entire study pop-
ulation (n5 115) was 81.7%, 52.2%, 49.6%, 61.7%, and 72.2%,
respectively, confirming previously reported numbers in HBV-
allergic patients (see Fig E1 in this article’s Online Repository
at www.jacionline.org).8 Demographic and clinical data (age,
sex, degree of anaphylaxis during index sting, treatment duration
before sting challenge, and previously suggested risk factors for
treatment failure) are summarized in Table I.
The comparison of responders (n 5 79) and nonresponders
(n5 36) before the initiation of VIT demonstrated no significant
difference in level of sIgE to Api m 1, Api m 2, Api m 3, and Api
m 5. In contrast, sIgE to HBVand to Api m 10was moderately but
significantly increased in nonresponders (Fig 1). We next
compared the percentage of sIgE directed against individual aller-
gens in relation to sIgE directed against the entire HBV (i1) in
both patient groups. Although no significant differences were
observed for Api m 1, Api m 2, and Api m 5, nonresponders dis-
played significantly increased percentage of sIgE to Api m 10 and
a slightly reduced percentage of sIgE toApim 3 in relation to sIgE
to the entire HBV (Fig 2). Similarly, nonresponders displayed
moderately but significantly increased percentage of sIgE to
Apim 10 in relation to total IgE (see Fig E2 in this article’s Online
Repository at www.jacionline.org).
On analyzing the ROCs of Api m 10 sIgE (AUC, 0.687;
P 5 .001) (Fig 3, A), the best discrimination between responders
and nonresponders (ie, the highest Youden’s index) was observed
at values of 1.82 kUA/L with a specificity of 70.9% (95% CI,
56.0% to 85.7%), a sensitivity of 69.4% (95% CI, 54.4% to
84.5%), a PLR of 2.39, and an NLR of 0.43. The cutoff of more
than 0.35 kUA/L provided a specificity of 34.2% (95% CI,
18.7% to 49.7%), a sensitivity of 83.3% (95% CI, 71.2% to
95.5%), a PLR of 1.27, and an NLR of 0.49. An Api m 10 sIgE
level of 26.55 kUA/L provided a specificity of 95% (95% CI,
90.0% to 100%), a sensitivity of 8.3% (95% CI, 0% to 17.4%),
a PLR of 2.19, and an NLR of 0.95.
ROC analysis of the percentage of Api m 10 sIgE in relation to
HBV sIgE (AUC, 0.667; P 5 .004) showed the best discrimina-
tion at 47.7%, with a specificity of 93.7% (95% CI, 85.7% to
100%), a sensitivity of 33.3% (95% CI, 17.9% to 48.7%), a
PLR of 5.28, and an NLR of 0.71. Specificity and sensitivity
levels at different percentages of Api m 10 sIgE to HBV sIgE
are displayed in Fig 3, B. When more than 50% of HBV sIgE
was directed against Api m 10, the test showed a specificity of
96.2% (95% CI, 90.0% to 100%) and a sensitivity of 25% (95%
CI, 10.9% to 39.1%), with a PLR of 6.58 and an NLR of 0.78.
This observation suggested that patients with a predominant
sensitization to Api m 10 are at a higher risk of VIT treatment fail-
ure. To address this relationship, we analyzed the ORs for
different percentage of sIgE to Api m 10 in relation to sIgE to
HBV. Indeed, increasing percentages of sIgE to Api m 10 (in rela-
tion to sIgE to HBV) were associated with increasing OR for
treatment failure (Fig 3, C). Notably, all subjects with sIgE to
TABLE I. Clinical data of patient population
Variable Responders (n 5 79) Nonresponders (n 5 36)
Age (y), mean (range) 40.1 (10-77) 41.4 (10-65)
Sex: F/M (%) 41.8/58.2 42.5/57.5
Total IgE (kUA/L), mean (range) 329.5 (2-9360) 245.6 (8-3525)
Systemic sting reaction,* n (%) I: 13 (16.5)
II: 49 (62.0)
III: 16 (20.3)
IV: 1 (1.3)
I: 2 (5.5)
II: 22 (61.1)
III: 11 (30.5)
IV: 1 (2.7)
Tryptase > 20 mg/L, or MIS (%) 4 of 79 (5.1) 1 of 36 (2.8)
Double VIT HBV & YJV (%) 21 of 79 (26.6) 7 of 36 (19.4)
Antihypertensive therapy (%) 10 of 79 (6.3) 3 of 36 (8.3)
ACE inhibitor medication (%) 1 of 79 (1.3) 0 of 36 (0)
Treatment duration before SC (mo), median (range) 31.4 (7-127) 37.3 (7-90)
ACE, Angiotensin-converting enzyme; F, female; M, male; MIS, mastocytosis in the skin; SC, sting challenge; YJV, yellow jacket venom.
*Highest degree of index sting reaction before VIT, clinical grade.16
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Api m 10 exceeding 60% of sIgE to HBV (n 5 8) were
treatment nonresponders. No such relationship was observed for
sensitization to Api m 1, Api m 2, Api m 3, or Api m 5 (see
Table E1 in this article’s Online Repository at www.jacionline.
org). Similarly, when comparing responders and nonresponders
regarding the induction of sIgG4 to HBV (i1), Api m 1, Api m
3, and Api m 10 during VIT, no significant differences were
observed (see Fig E3 in this article’s Online Repository at
www.jacionline.org).
Analysis of Api m 1, Api m 3, and Api m 10 in crude
and therapeutic HBV preparations
The initial evidence for the absence or underrepresentation of
Api m 10 and Api m 3 in therapeutic HBV preparations was
obtained using recombinant IgE antibodies isolated by
combinatorial technologies.13 To provide a more solid basis for
analyzing the presence of allergens in crude and therapeutic
HBV preparations, specific polyclonal antisera were generated
in rabbits immunized with Api m 1, Api m 3, or Api m 10 (see
Fig E4 in this article’s Online Repository at www.jacionline.
org). On applying these polyclonal antibodies in immunoblot
analysis of 2 different sources of crude HBV, we found that all
sera detected the corresponding proteins at the expected size
and with comparable intensity. For Api m 3 and Api m 10, bands
at 55 and 50 kDa, respectively, were detected (Fig 4, A and B). For
Api m 1, 3 bands were detected at 15 to 20 kDa, representing the
main glycoforms (Fig 4, C). In addition, 5 different therapeutic
HBV preparations were analyzed at identical concentrations
(1 mg/mL), all of which exhibited a clear reactivity with antisera
directed to Apim 1 andApim 3, comparable to that of crude HBV
(Fig 4, B and C). However, in contrast to crude HBV, only 2 of 5
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FIG 1. Serum IgE reactivity to HBV (i1), Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10 in HBV-allergic
patients before the initiation of HBV immunotherapy. All patients were classified as either responder
(n 5 79) or nonresponder (n 5 36) on the basis of absence or presence of systemic allergic reactions upon
sting challenge. The number of sera that displayed sIgE concentrations of less than 0.1 kUA/L are displayed
below the dashed line (solid line, geometric mean). ns, Not significant.
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therapeutic HBV preparations showed reactivity for the Api m
10–specific antiserum at a level comparable to that detected in
crude venom when tested at a concentration of 0.3 mg/mL. These
data corroborate the absence (or significant underrepresentation)
of Api m 10 in some therapeutic HBV preparations (Fig 4, A).
Comparison of Api m 10–specific sIgE and IgG4
responses in patients treated with different HBV
preparations
Differences in Api m 10 concentrations among therapeutic
HBV preparations prompted us to compare Apim 10–specific IgE
and IgG4 responses in patients who had received VIT using HBV
preparations with low or no Api m 10 (group I, n5 59) and those
who had received VIT using a HBV preparation with well-
detectable Api m 10 immunoreactivity (group II, n 5 50). VIT
induced a moderate but significant reduction in sIgE to Api m
10 in both treatment groups (Fig 5, A). In contrast, significant in-
duction of sIgG4 was observed only in those patients treated
with the HBV that contained detectable amounts of Api m 10
(group II, Fig 5, B).
DISCUSSION
Treatment failure in HB VIT has been suggested to be
associated with the complexity of venom composition and the
presence of individual sensitization profiles.5-8 Additional risk
factors include elevated baseline serum tryptase, concomitant
mast cell disorders,6,18,19 systemic allergic reactions during VIT
build-up or maintenance phase, and angiotensin-converting
enzyme inhibitor medication at the time of sting challenge.6
For the present study, patient charts were analyzed for evidence
of known risk factors to exclude potential confounder effects. As
summarized in Table I, both patient groups were comparable with
regard to age, sex distribution, antihypertensive therapy, in partic-
ular ACE inhibitor medication, percentage of double VIT, and
treatment duration. When analyzing the highest degree of sting
reaction before VIT, in the present study nonresponders displayed
a higher percentage of severe reactions (grades III and IV) as
compared with responders (33.2% vs 21.6%). However, as
recently demonstrated in a larger patient cohort, the degree of
sting reaction before VIT does not appear to be a relevant risk fac-
tor for treatment failure.6 A second potential difference was the
percentage of patients with elevated serum tryptase concentra-
tions and/or mastocytosis in the skin, which was lower among
rApi m 1 rApi m 2
rApi m 3 rApi m 5 rApi m 10
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FIG 2. Percentage of sIgE directed against individual allergens in relation to IgE directed against the entire
HBV (i1) in HBV-allergic patients (responders, n 5 79, and nonresponders, n 5 36) before the initiation of
HBV immunotherapy. ns, Not significant.
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nonresponders than among responders (2.8% vs 5.1%). Because
both parameters have been associated with increased risk of treat-
ment failure, we would have expected the opposite and assume
that this difference is random, that is, result of the relatively small
study populations and thus does not constitute a relevant
confounder for the present study.
A comparison of sensitization profiles to the panel of recom-
binant HBV allergens used in this study demonstrated an
increased degree of IgE sensitization to Api m 10 among the
nonresponders, while no significant differences were observed for
the other allergens. The best discrimination between responders
and nonresponders was calculated at Api m 10 sIgE levels of 1.82
kUA/L with a specificity of 71% and a sensitivity of 70%. To
obtain a specificity of 95%, an Api m 10 sIgE level of 26.55
kUA/L was required, which resulted in a drop of sensitivity to
8.3%. In conclusion, the ROCs of Api m 10 sIgE as a single
parameter, although significant (AUC, 0.687; P 5 .001), were
far from optimal for identifying patients who were at risk to be
not protected by HBV immunotherapy.
We speculated that the percentage of Api m 10 sIgE in relation
toHBV sIgE (or to total serum IgE)may bemore relevant. Indeed,
the ROCs of the percentage of Api m 10 sIgE (in relation to HBV
sIgE) displayed a better performance. When more than 50% of
HBV sIgE was directed against Api m 10, the test showed a
specificity of 96.2%, a sensitivity of 25%, and an OR of 8.44 for
treatment failure. No such relationship was observed for Api m 1,
Api m 2, Api m 3, and Api m 5 (Table E1). Similar results were
obtained when the percentage of Api m 10 sIgE in relation to total
Se
ns
iƟ
vi
ty
[%
]
100 - Specificity [%]
0
0
20 40 60 80 100
100
80
60
40
20
Api m 10 sIgE = 1.82 KUA/L (spec 70.9%,  sens 69.4%) 
Api m 10 sIgE > 0.35 KUA/L (spec 34.2%,  sens  83.3%)
Api m 10 sIgE = 26.55 KUA/L (spec > 95%,  sens 8.4%)
ROC Api m 10 sIgE
100 - Specificity [%]
0
0
20 40 60 80 100
100
80
60
40
20
47.7%  (spec 93.7%, sens 33.3% )
Percentage of Api m 10 sIgE to HBV sIgE
ROC analysis
> 20% (spec 65.8%, sens 55.6%)
> 10% (spec 44.3%, sens 72.2%)
> 30% (spec 83.5%, sens 38.9%)
> 40% (spec 89.9%, sens 33.3% )
> 50% (spec 96.2%, sens 25.0% )
Se
ns
iƟ
vi
ty
[%
]
> 1
0%
> 2
0%
> 3
0%
> 4
0%
> 5
0%
> 6
0%
> 7
0%
> 8
0%
> 9
0%
0.1
1
10
100
1000
Percentage of Api m 10 sIgE to HBV sIgE (i1)
O
R *
** *** * **
**
**
ns
ns
*
A B
C
FIG 3. A, ROC analysis of Api m 10 sIgE (AUC 0.687; P 5 .001) that display true positivity rate (sensitivity)
plotted against false-positive rate (specificity) for different cutoff points. Black circle: WHO cutoff point
for sIgE level of 0.35 kUA/L or more; black square: highest Youden’s index, that is, point of best discrimina-
tion between responders and nonresponders; black triangle: Api m 10 sIgE level at which a specificity of
more than 95% is reached. B, ROC analysis of the percentage of Api m 10 sIgE in relation to HBV sIgE
(AUC, 0.667; P 5 .004). Black square: highest Youden index, that is, point of best discrimination between
responders and nonresponders; black triangles: specificity and sensitivity at different percentage levels
of Api m 10 sIgE in relation to HBV sIgE. C, Calculated ORs for different percentage levels of sIgE to Api
m 10 in relation to sIgE to HBV (i1) in HBV-allergic patients before the initiation of VIT. (A, B, C: responders,
n5 79, nonresponders, n5 36). *P < .05, **P < .01, and ***P < .001. ns, Not significant; WHO, World Health
Organization.
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IgE was analyzed (see Figs E2 and E5 in this article’s Online Re-
pository at www.jacionline.org). However, the performance char-
acteristics were less favorable, which may be due to a smaller
group size and/or the fact that for a large proportion of the patients
total IgE concentrations had not been analyzed in parallel with
sIgE but in different laboratories. For most patients, serum sam-
ples were also available, which were obtained before the sting
challenge. Again, nonresponders displayedmoderately but signif-
icantly increased levels of sIgE to Api m 10 (see Fig E6 in this ar-
ticle’s Online Repository at www.jacionline.org) and an increased
percentage of sIgE to Api m 10 in relation to HBV sIgE (i1) (see
Fig E7 in this article’s Online Repository at www.jacionline.org)
but not as prominently as in samples that were taken before initi-
ation of VIT. In conclusion, the best test performance was ob-
tained when analyzing the percentage of Api m 10 sIgE in
relation to HBV sIgE before initiation of VIT. These data sug-
gested that a predominant (>50%) sensitization to Api m 10 rep-
resents a relevant risk factor for VIT treatment failure in HBV
allergy.
In this context, we reinvestigated the presence of Api m 1, Api
m 3, andApim 10 in different HBV preparations using polyclonal
rabbit antisera in order to corroborate findings previously
obtained using recombinant human IgE antibodies.13Monoclonal
antibodies with high specificity for one epitope only might be
more susceptible for interference by loss of epitope structures
by unfolding, protein fragmentation, or isoform variation and
thus might exhibit a lower sensitivity. We could demonstrate
the presence of Api m 1 and Api m 3 in all tested HBV prepara-
tions. In contrast and consistent with our previous report, Api m
10 was underrepresented in 3 of 5 therapeutic HBV preparations
while present in both crude HBV preparations analyzed (Fig 4).
Notably, the lack of additional bands for Api m 10makes the pres-
ence of putative Api m 10 isoforms with significantly variant mo-
lecular mass unlikely. This finding also suggests that the absence
of Api m 10 in some of the therapeutic HBV preparations is not
mainly caused by protein fragmentation.
Currently we speculate that processing/purification of the
crude HBV during the manufacturing process may lead to the
loss of Api m 10 immunoreactivity. In this context, it is of interest
that Api m 10 was detectable in nonprocessed HBV preparations
(as in Pharmalgen, ALK-Abello), whereas it was not detectable in
therapeutic HBV preparations that have been processed/purified
to reduce low molecular weight substances (such as Aquagen,
ALK-Abello). This step has been introduced to exclude vasoac-
tive mediators and small bioactive peptides that have been
associated with local side effects of VIT.20,21 Because direct
loss of Api m 10 on the basis of molecular size is unlikely, other
indirect mechanisms during the manufacturing process may be
involved andmust be addressed for each product by the respective
manufacturer.
The analysis of allergen-specific IgG4 levels before and under
VIT demonstrated robust induction of sIgG4 directed against
HBV or Api m 1 but no or little against Api m 3 and Api m 10
(Fig E3). This difference may be due to the quantities of allergens
in the HBV. Although Api m 1 represents a highly abundant
allergen that constitutes up to 12% of the HBV dry weight, both
Api m 3 and Api m 10 are present in much smaller quantities
(1% to 2% and <1%, respectively).15 Induction of IgG4 to any
of the allergens did not allow discrimination between responders
and nonresponders (Fig E3). Interestingly, when patients were
stratified according to the type of venom used for VIT, a low
but significant induction of sIgG4 to Api m 10 was observed
FIG 4. Presence of individual allergens in crude HBV and 5 different therapeutic HBV preparations. The
presence of Api m 10 (A), Api m 3 (B), and Api m 1 (C) in 2 different crude and 5 different therapeutic
preparations (I: Venomil, Allergy Therapeutics, Worthing, UK; II: Venomenhal, HAL Allergy, Leiden, the
Netherlands; III: Aquagen, ALK-Abello, Hamburg, Germany; IV: Pharmalgen, ALK-Abello; V: Alyostal Venin,
Stallergenes, Antony, France) using allergen-specific rabbit polyclonal anti–Api m 1, anti–Api m 3, and
anti–Api m 10 antibodies was assessed by immunoblotting. Representative data of 3 different batches
tested for I, III, IV, and V, and 2 different batches tested for II.
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only in those patients treated with the HBV that contained detect-
able amounts of Api m 10.
The present study has clear limitations in that it used a
retrospective study design using a limited number of stored sera
and corresponding clinical data from patients seen at 6 different
allergy clinics. The differences observed were relatively small but
consistent regardless of the way they were calculated (Api m 10
sIgE values, percentage of Api m 10 sIgE to HBV sIgE, or
percentage of Api m 10 sIgE to total IgE). The ROCs and the
PLRs of these parameters are clearly less impressive than those of
other risk markers, such as Ara h 2 in peanut allergy. This may be
related to the fact that risk markers such as Ara h 2 are used in the
diagnostic setting to detect IgE sensitizations associated with
increased risk of severe allergic reactions including anaphylaxis.
In contrast, we have used component-resolved diagnostics to
address whether certain sensitization profiles are associated with
different treatment outcomes, that is, an increased risk not to
benefit from VIT. In this setting, the hurdle may be even higher to
detect significant and clinically useful differences because more
variables may influence the outcome of the therapeutic approach.
Despite these limitations, we provide for the first time evidence
that patients with a predominant sensitization to Api m 10 are at
increased risk of not becoming protected by HBV immuno-
therapy. In addition, we demonstrate that some but not all
therapeutic HBV preparations lack Api m10 and that sIgG4 re-
sponses depend on the presence of Api m 10 in the VIT prepara-
tion. Given the quite recent availability of Api m 10 on a widely
used test platform, it appears justified to recommend that (a) sIgE
to Api m 10 should be tested in HBVallergy and (b) patients with
a predominant Api m 10 sensitization should be treated with a
HBV preparation in which the presence of a relevant amount of
Api m 10 has been documented. Additional evidence to support
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this notion will require prospective studies in which the treatment
efficacy of HBV preparations with and without Api m 10 is
compared and related to initial component-resolved sensitization
profiles.
We are grateful for the expert technical assistance of Andrea Komann and
Heike Neuman, Freiburg, Germany. Ulrica Olsson and Lars J€orts€o (Phadia,
Uppsala, Sweden) are gratefully acknowledged for the preparation of
experimental ImmunoCAP tests.
Clinical implications: HBV-allergic patients with dominant
sensitization to Api m 10 are at increased risk for treatment fail-
ure in HBV immunotherapy and should benefit from treatment
with Api m 10–containing preparations.
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METHODS
Allergens and IgE and IgG4 antibody measurements
Recombinant Api m 2, Api m 3, and Api m 5 were expressed as secreted
full-length proteins by Spodoptera frugiperda (Sf9) insect cells as recently
described.E1-E4 Api m 10 was expressed in Escherichia coli. Experimental
ImmunoCAP tests (Phadia AB, Uppsala, Sweden) containing the purified
HBVallergens were prepared as described.E5 In addition, commercially avail-
able ImmunoCAPs for sIgE to HBV (i1) and Api m1 (i208) and total IgE were
used. All IgE and IgG4 antibodymeasurements were performed using a Phadia
250 instrument according to the manufacturer’s instructions (Thermo Fischer
Scientific, Uppsala, Sweden). The cutoff level for positive/negative sIgE sensi-
tization (>_0.35 kUA/L) is indicated as dotted line (Fig E1). sIgE levels below
0.1 kUA/L were set at 0.1 kUA/L for statistical analysis and displayed sepa-
rately as less than 0.1 kUA/L in Figs 1 and 5, A. sIgG4 antibody measurements
were performed at a serum dilution of 1:100 for HBVandApim 1 according to
the manufacturer’s instructions. The LOD for sIgG4 was calculated as 896 22
mgA/L as described.
E6 Thus, levels below 100mgA/Lwere set at 100mgA/L for
statistical analysis and displayed separately as less than 100 mgA/L in the
figures. sIgG4 for Api m 3 was analyzed at a 1:20 and for Api m 10 at a 1:5
dilution and values were calculated and displayed accordingly.
Generation of antisera
Recombinantly produced allergens Api m 1, Api m 3, and Api m 10 were
used for immunization of rabbits according to established protocols.
Immunoreactivity and specificity of the resulting antisera were assessed by
ELISA using recombinant HBV proteins (Fig E3). Purified recombinant Api
m 1, Api m 2, Api m 3, Api m 5, and Api m 10 (10 mg/mL) were coated on
384-well microtiter plates (Greiner, Frickenhausen, Germany) at 48C over-
night and blocked with 40 mg/mL milk powder in PBS. Thereafter, antisera
were diluted 1:5.000-20.000 with 2%milk powder in TBS and were incubated
in a final volume of 50 mL for 2 hours at room temperature and applied to the
corresponding wells. After washing 4 times with T-PBS and PBS, alkaline
phosphatase–conjugated antirabbit IgG antibodies diluted 1:30.000 in
20 mg/mL milk powder in PBS were added for 1 hour at room temperature.
Signals were detected after washing 4 times with T-PBS and PBS and subse-
quent addition of 50 mL of substrate solution.
Immunoblot analyses of venom and VIT
preparations
Crude venoms were obtained from Latoxan (Valence, France) and
Entomon (Florence, Italy). The VIT preparations we assessed included
Pharmalgen (ALK-Abello), Alyostal Venin (Stallergenes), Aquagen (ALK-
Abello), Venomhal (HAL Allergy), and Venomil (Allergy Therapeutics). For
immunoblot procedures, crude venom as well as the therapeutic venom
preparations were dissolved to a stock concentration of 1 mg/mL. Amounts of
5 mL for detection of Api m 1, Api m 3, and Api m 10 were separated under
reducing conditions by SDS-PAGE using Criterion XT (12%) Bis-Tris gels
andMES buffer (Biorad,Munich, Germany) and transferred by wet blotting in
Towbin buffer onto nitrocellulose membranes (Roth, Karlsruhe, Germany).
The membranes were blocked with 4% milk powder in TBS buffer. Allergen-
specific sera were diluted 1:5.000-50.000 with 2% milk powder in TBS and
applied to the correspondingmembranes. Visualization of bound IgGwas then
performed with goat antirabbit IgG conjugated to alkaline phosphatase
(Sigma-Aldrich, Hamburg, Germany) diluted 1:20.000 in 2% milk powder
in TBS and nitrotetrazolium blue chloride/x-phos (Sigma-Aldrich, Hamburg,
Germany) according to the recommendations of the manufacturer.
RESULTS
Prevalence of IgE sensitization to HBV allergens in
HBV-allergic patients
Prevalence of IgE sensitization to HBV allergen components
among the 115 HBV-allergic patients included in the study (sIgE
to Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10) is displayed
in Fig E1.
IgE reactivity to Api m 10 in relation to total IgE
Although no significant differences were observed for the
percentage of sIgE to HBV, Api m 1, Api m 2, Api m 3, and
Api m 5, nonresponders displayed moderately but significantly
increased percentage of sIgE to Api m 10 in relation to total IgE
(Fig E2).
ROC analysis of the percentage of Api m 10 sIgE in relation to
total serum IgE (AUC, 0.659; P5 .009) showed the best discrim-
ination between responders and nonresponders at 2.9%, with a
specificity of 77.3% (95% CI, 63.7% to 91.0%) and a sensitivity
of 54.5% (95% CI, 38.3% to 70.8%) with a PLR of 2.40 and an
NLR of 0.58. Specificity and sensitivity levels at different
percentages of Api m 10 sIgE to total IgE are displayed in
Fig E5. When more than 11% of total IgE was directed against
Api m 10, the test showed a specificity of 95% (95% CI, 89.6%
to 100%), a sensitivity of 18.2% (95% CI, 5.6% to 30.8%), a
PLR of 4.55, and an NLR of 0.85.
IgG4 reactivity to HBV allergens before and during
VIT
For the analysis of IgG4 responses, paired samples obtained
before and after at least 6 months of VIT (ie, before sting chal-
lenge) were available from 73 responders and 35 nonresponders.
Before VIT, sIgG4 to HBVand to Api m 1 was detectable in most
of the samples both in responders and in nonresponders (Fig E3,
A). In contrast, sIgG4 to Api m 3 and Api m 10 was detectable at a
much lower level and a substantial proportion of the patients’ sera
were below the detection limit of the assay (25 of 73 responders,
10 of 35 nonresponders). Following at least 6 months of VIT, a
prominent induction of sIgG4 was observed for the highly abun-
dant allergen Api m 1, comparable to that observed for whole
HBV (Fig E3, A and B). In contrast, no significant induction of
sIgG4 to Api m 3 and only a minor increase in sIgG4 to Api m
10 was observed in both responders and nonresponders (Fig E3,
A). Patients’ samples with sIgG4 levels above the cutoff of the
assay at both time points were used to calculate the ratio of
sIgG4 during/before VIT. On comparing responders and nonre-
sponders regarding the degree of sIgG4 induction, no significant
difference was observed for any of the parameters (Fig E3, B).
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FIG E1. Prevalence of IgE sensitization to HBV allergen components among the 115 HBV-allergic patients
included in the study (sIgE to Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10). The cutoff level for positive
sensitization (>_0.35 kUA/L) is indicated as dotted line, and the lower limit of quantification (>_0.10 kUA/L) is
indicated as dashed line.
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FIG E2. Percentage of sIgE to HBV, Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10 in relation to total IgE in
HBV-allergic patients before the initiation of VIT. All patients were classified as either responder (n 5 75) or
nonresponder (n 5 33) on the basis of the absence or presence of systemic allergic reactions upon sting
challenge. Please note that because of lacking total IgE values, 4 responder sera and 3 nonresponder sera
could not be included in this calculation. ns, Not significant.
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FIG E3. A, Serum IgG4 reactivity to HBV (i1), Api m 1, Api m 3, and Api m 10 in HBV-allergic patients (re-
sponders, n 5 73; nonresponders; n 5 35) before initiation and after at least 6 months of HBV immuno-
therapy. The number of sera that displayed sIgG4 concentrations below the LOD of the assay is displayed
below the dashed line. B, Samples with sIgG4 levels above the LOD of the assay at both time points were
used to calculate the ratio of sIgG4 during/before VIT. LOD, Limit of detection; ns, not significant.
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FIG E4. Specificity and immunoreactivity of antibodies against Api m 1, Api
m 3, and Apim 10. The specificity of the polyclonal antisera against Api m 1,
Api m 3, and Api m 10 was assessed by ELISA using recombinant HBV
allergens Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10.
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FIG E7. Percentage of sIgE directed against individual allergens in relation to IgE directed against the entire
HBV (i1) in HBV-allergic patient (responders, n 5 71, and nonresponders, n 5 35) under VIT before sting
challenge. Please note that 3 responder sera were excluded because sIgE to HBV (i1) had fallen below 0.35
kUA/L. ns, Not significant.
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TABLE E1. ORs for nonresponding to VIT were calculated for different percentages of sIgE directed against individual HBV
allergens (Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10) in relation to sIgE to the entire HBV (i1) in HBV-allergic patients before
the initiation of VIT
sIgE Api m 1 in relation
to sIgE HBV (i1) n of responders n of nonresponders OR CI P value
>10% 60 of 79 31 of 36 1.963 0.669-5.762 NS
>20% 48 of 79 25 of 36 1.468 0.633-3.403 NS
>30% 36 of 79 21 of 36 1.672 0.754-3.711 NS
>40% 31 of 79 17 of 36 1.385 0.625-3.069 NS
>50% 30 of 79 14 of 36 1.039 0.463-2.336 NS
>60% 22 of 79 8 of 36 0.740 0.293-1.871 NS
>70% 15 of 79 5 of 36 0.688 0.229-2.066 NS
>80% 13 of 79 4 of 36 0.635 0.192-2.102 NS
>90% 11 of 79 3 of 36 0.544 0.147-2.153 NS
sIgE Api m 2 in relation
to sIgE HBV (i1) n of responders n of nonresponders OR CI P value
>10% 38 of 79 12 of 36 0.539 0.237-1.227 NS
>20% 21 of 79 7 of 36 0.667 0.254-1.750 NS
>30% 15 of 79 3 of 36 0.388 0.105-1.436 NS
>40% 14 of 79 1 of 36 0.133 0.017-1.052 .0347
>50% 9 of 79 1 of 36 0.222 0.027-1.826 NS
>60% 8 of 79 1 of 36 0.254 0.030-2.109 NS
>70% 5 of 79 1 of 36 0.423 0.048-3.759 NS
>80% 3 of 79 1 of 36 0.724 0.073-7.211 NS
>90% 3 of 79 0 of 36 0.299 0.015-5.954 NS
sIgE Api m 3 in relation
to sIgE HBV (i1) n of responders n of nonresponders OR CI P value
>10% 31 of 79 8 of 36 0.442 0.179-1.095 NS
>20% 8 of 79 4 of 36 1.109 0.311-3.954 NS
>30% 5 of 79 1 of 36 0.423 0.048-3.759 NS
>40% 3 of 79 1 of 36 0.724 0.073-7.211 NS
>50% 2 of 79 1 of 36 1.10 0.096-12.55 NS
>60% 2 of 79 1 of 36 1.10 0.096-12.55 NS
>70% 2 of 79 1 of 36 1.10 0.096-12.55 NS
>80% 2 of 79 0 of 36 0.425 0.019-9.080 NS
>90% 1 of 79 0 of 36 0.717 0.028-18.04 NS
sIgE Api m 5 in relation
to sIgE HBV (i1) n of responders n of nonresponders OR CI P value
>10% 38 of 79 13 of 36 0.609 0.271-1.372 NS
>20% 21 of 79 7 of 36 0.667 0.254-1.750 NS
>30% 15 of 79 3 of 36 0.388 0.105-1.436 NS
>40% 13 of 79 2 of 36 0.299 0.064-1.401 NS
>50% 12 of 79 2 of 36 0.328 0.069-1.552 NS
>60% 7 of 79 2 of 36 0.605 0.119-3.069 NS
>70% 3 of 79 2 of 36 1.490 0.238-9.334 NS
>80% 2 of 79 0 of 36 0.425 0.019-9.080 NS
>90% 2 of 79 0 of 36 0.425 0.019-9.080 NS
sIgE Api m 10 in relation
to sIgE HBV (i1) n of responders n of nonresponders OR CI P value
>10% 48 of 79 26 of 36 1.679 0.712-3.960 NS
>20% 27 of 79 21 of 36 2.696 1.200-6.059 .0242
>30% 14 of 79 14 of 36 2.955 1.220-7.157 .0194
>40% 8 of 79 12 of 36 4.438 1.620-12.15 .0064
>50% 3 of 79 9 of 36 8.444 2.127-33.53 .0013
>60% 0 of 79 8 of 36 47.42 2.649-848.8 .0001
>70% 0 of 79 6 of 36 33.89 1.851-620.3 .0007
>80% 0 of 79 4 of 36 22.02 1.151-421.0 .0085
>90% 0 of 79 1 of 36 6.718 0.267-169.1 NS
NS, Not significant.
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